Healthtech Investors & VC Firms in Israel

76 firms in this list, with a median first check of $1.3M. 4 of them lead rounds. Generated from verified public data and updated continuously.

Fund	FoxScore	HQ	Invests	Stage	Check	CRM
HE Hercules Capital, Inc. BJCJGPJB11 people	88🔒	San Mateo	US	Seed–Late Stage	$500K – $50M	+ Add to CRM
JJ JJDC FMHPLTTM11 people	88🔒	New Brunswick	US	Seed–Series B	$500K – $5M	+ Add to CRM
MC MCI Capital S.A. EOFBMGPS11 people	88🔒	Warsaw	PL	Growth	$27M – $108M	+ Add to CRM
VI Viola Credit AGEFIVNM11 people	88🔒	Tel Aviv	IL	Growth–Late Stage	$2M – $50M	+ Add to CRM
PA Panakes Partners ABDSFLBC11 people	88🔒	Milan	IT	Seed–Late Stage	—	+ Add to CRM
PL Planven Entrepreneur Ventures EWGCMGEV8 people	88🔒	Zürich	CH	Seed–Late Stage	$5M – $10M	+ Add to CRM
SE Serendipity Impact VC AYDMSBAT5 people	88🔒	New York	US	Seed–Series B	—	+ Add to CRM
WH WHC BAGEAADK5 people	88🔒	Delaware	US	Pre-Seed–Seed	—	+ Add to CRM
FE Ferocity Capital KVSWTM3 people	88🔒	—		—	—	+ Add to CRM
TR Trilogy Equity Partners AMCSPVTG7 people	88🔒	Bellevue	US	Seed–Late Stage	$2M – $4M	+ Add to CRM
NI Nina Capital MGMSSAYH6 people	88🔒	Barcelona	ES	Pre-Seed–Series A	$216K – $1.6M	+ Add to CRM
RO Romulus Capital JKKKNCWC6 people	88🔒	Boston	US	Seed–Late Stage	$250K – $10M	+ Add to CRM
SC SCP Vitalife Partners ALJDWBWJ6 people	88🔒	Wayne	US	Series A–Late Stage	$3M – $7M	+ Add to CRM
SO Sound Media Ventures SOMB2 people	88🔒	Atlanta	US	Pre-Seed–Series A	—	+ Add to CRM
CA Catalyst Investments, L.P. ECYSAABH5 people	88🔒	Tel Aviv	IL	Growth	$1.5M – $5M	+ Add to CRM
CR Cross-Border Impact Ventures ATDPMDCA5 people	88🔒	Toronto	CA	Series A–Series B	$2M – $10M	+ Add to CRM
DE Debiopharm Innovation Fund MCTGVLCO5 people	88🔒	Lausanne	CH	Series A–Late Stage	$3M – $5M	+ Add to CRM
LA Laerdal Million Lives Fund JTBSDSJJ5 people	88🔒	San Francisco	US	Series A–Series B	$1M – $5M	+ Add to CRM
10 10D AKIRREYZ6 people	88🔒	Tel Aviv	IL	Seed–Series A	—	+ Add to CRM
ES Esplanade Ventures SESMEBAN6 people	88🔒	Westmount	CA	Seed–Series A	—	+ Add to CRM
IN Industrial Technology Investment Corporation ACBTKYLC6 people	88🔒	Taipei	TW	Seed–Late Stage	—	+ Add to CRM
ME Medical Incubator Japan K.K. AKDKKHLT6 people	88🔒	Tokyo	JP	Series A–Series B	—	+ Add to CRM
AL Almeda Ventures ABIYTSEH5 people	88🔒	Tel Aviv	IL	Seed–Late Stage	—	+ Add to CRM
FL Flint Capital AGDSSGDF5 people	88🔒	Boston	US	Pre-Seed–Late Stage	—	+ Add to CRM

Hercules Capital, Inc.

San MateoSeed–Late Stage$500K – $50M

BJCJGPJB11 people

JJDC

New BrunswickSeed–Series B$500K – $5M

FMHPLTTM11 people

MCI Capital S.A.

WarsawGrowth$27M – $108M

EOFBMGPS11 people

Viola Credit

Tel AvivGrowth–Late Stage$2M – $50M

AGEFIVNM11 people

Panakes Partners

MilanSeed–Late Stage

ABDSFLBC11 people

Planven Entrepreneur Ventures

ZürichSeed–Late Stage$5M – $10M

EWGCMGEV8 people

Serendipity Impact VC

New YorkSeed–Series B

AYDMSBAT5 people

WHC

DelawarePre-Seed–Seed

BAGEAADK5 people

Ferocity Capital

KVSWTM3 people

Trilogy Equity Partners

BellevueSeed–Late Stage$2M – $4M

AMCSPVTG7 people

Nina Capital

BarcelonaPre-Seed–Series A$216K – $1.6M

MGMSSAYH6 people

Romulus Capital

BostonSeed–Late Stage$250K – $10M

JKKKNCWC6 people

SCP Vitalife Partners

WayneSeries A–Late Stage$3M – $7M

ALJDWBWJ6 people

Sound Media Ventures

AtlantaPre-Seed–Series A

SOMB2 people

Catalyst Investments, L.P.

Tel AvivGrowth$1.5M – $5M

ECYSAABH5 people

Cross-Border Impact Ventures

TorontoSeries A–Series B$2M – $10M

ATDPMDCA5 people

Debiopharm Innovation Fund

LausanneSeries A–Late Stage$3M – $5M

MCTGVLCO5 people

Laerdal Million Lives Fund

San FranciscoSeries A–Series B$1M – $5M

JTBSDSJJ5 people

10D

Tel AvivSeed–Series A

AKIRREYZ6 people

Esplanade Ventures

WestmountSeed–Series A

SESMEBAN6 people

Industrial Technology Investment Corporation

TaipeiSeed–Late Stage

ACBTKYLC6 people

Medical Incubator Japan K.K.

TokyoSeries A–Series B

AKDKKHLT6 people

Almeda Ventures

Tel AvivSeed–Late Stage

ABIYTSEH5 people

Flint Capital

BostonPre-Seed–Late Stage

AGDSSGDF5 people

Data sourced from public filings and firms' own websites — see our methodology.